Transgene Biotek Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue growth from ₹0.04 crore to ₹0.06 crore in Q2 FY2024 indicates potential recovery.
Operating profit turned positive in Q2 FY2024, showcasing improved efficiency.
Other income saw a significant jump to ₹0.65 crore in Q2 FY2024, enhancing overall financials.

NEGATIVES

Net profit remains negative, peaking at -₹0.71 crore in Q1 FY2025, raising concerns.
Expense growth outpaced revenue, indicating potential margin pressures.
Profit before tax fluctuated, with a negative shift in Q1 FY2025, highlighting instability.

Field	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	0.10	0.04	0.04	0.04	0.05	0.06	0.08	0.08	0.05
Expenses	0.22	0.17	0.15	0.31	0.46	0.14	0.17	0.62	0.19
Operating Profit	-0.12	-0.12	-0.11	-0.27	-0.41	-0.08	-0.09	-0.54	-0.14
Other Income	0.04	0.04	0.04	0.05	0.65	0.04	0.04	0.04	0
Interest	0.03	0.03	0.03	0.03	0.02	0.02	0.02	0.19	0.25
Depreciation	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.05
Profit Before Tax	-0.13	-0.13	-0.12	-0.27	0.20	-0.07	-0.09	-0.71	-0.43
Tax	0	0	0	0	0	0	0	0	0
Net Profit	-0.13	-0.13	-0.12	-0.27	0.20	-0.07	-0.09	-0.71	-0.43
Eps in Rs	-0.02	-0.02	-0.02	-0.04	0.03	-0.01	-0.01	-0.09	-0.06